Intralobar pulmonary sequestration receiving arterial supply from the superior mesenteric artery: a case report.

We report a case of congenital anomaly of pulmonary sequestration by contrast-enhanced three-dimensional magnetic resonance (MR) angiography and digital subtraction angiography (DSA). The pulmonary sequestration receives a blood supply from the superior mesenteric artery. MR angiography technique has been employed in pulmonary sequestration.

Uterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings.

Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenofibroma and endometrial stromal sarcoma (ESS). This report describes the MR findings of adenofibroma and ESS associated with tamoxifen therapy. When MRI demonstrates a uterine mass appearing as a heterogeneous mass in the endometrium or myometrium, adenofibroma and ECC must be considered as rare, but possible, diagnoses.

Dialyzability of gadodiamide in hemodialysis patients.

PURPOSE: The aim of this study was to evaluate the contrast enhancement, pharmacokinetics, dialyzability, and safety of gadodiamide in patients on hemodialysis. MATERIALS AND METHODS: Thirteen hemodialysis patients with abdominal disease were examined after receiving intravenous gadodiamide (0.1 mmol/kg body weight) by magnetic resonance imaging (MRI) and were dialyzed at l, 3, 5, and 8 days. Blood samples were obtained immediately before, during, and at the end of the first hemodialysis session and immediately before and at the end of the next three sessions. The complete blood count, blood biochemistry, beta2-microglobulin, and gadolinium were measured. Dialysis of urea, creatinine, and gadolinium during the first hemodialysis session was assessed. Precontrast and postcontrast MRI and Gd-enhanced MR angiography (MRA) images were reviewed and visually evaluated by two radiologists; their evaluation was based on consensus. RESULTS: Gadodiamide did not cause any changes in renal function. An average of 73.8%, 92.4%, and 98.9% of the gadodiamide dose was eliminated by the end of the first, second, and third hemodialysis sessions, respectively. The average half-time of gadodiamide was 1.93 h (SD 0.55). The mean clearance of gadodiamide during hemodialysis was 63.5 ml/min (SD 21.9). There were no side effects related to the injection of gadodiamide. In all cases, diagnosable MRI and MRA images were obtained after gadodiamide injection in the hemodialysis patients. CONCLUSION: In hemodialysis patients, gadodiamide achieves diagnosable images. It is dialyzable and can be used safely without measures to increase excretion.

Gadolinium-enhanced dynamic MRI of breast hemangioma.

We describe a patient with hemangioma of the breast. The tumor showed an Ill-defined hypointense mass on T1-weighted imaging and hyperintense mass on T2-weighted imaging. After bolus gadolinium injection, the tumor showed heterogeneous enhancement in early phase and in the time-intensity an early intensive enhancement was followed by a plateau. This intensive enhancement in the early phase is not limited to breast carcinoma but can be found in breast hemangiomas as well.